DARATUMUMAB SHOWS REMARKABLE BENEFIT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN THE POLLUX STUDY

Dr Meletios A Dimopoulos (Abstract LB2238):

   

IMMUNOTHERAPY DELIVERED BY BLINATUMOMAB IMPROVES SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKAEMIA PATIENTS (TOWER-Study)

Dr Max S Topp (Abstract S149):

   

Comment Prof. Dr. med. Markus Manz, Klinikdirektor,

Klinik für Hämatologie, UniversitätsSpital Zürich: 

 

THE ROOT OF EVIL: PRE-LEUKEMIC CLONES THAT SURVIVE CHEMOTHERAPY ARE LINKED TO A HIGHER RISK OF LEUKEMIA RECURRENCE

Dr Klaus Metzeler (Abstract S146):

   

STOPPING TYROSINE KINASE INHIBITORS IN A VERY LARGE COHORT OF EUROPEAN CHRONIC MYELOID LEUKEMIA PATIENTS: RESULTS OF THE EURO-SKI TRIAL

Dr Johan Richter (Abstract S145):

   

MAJOR BLEEDING IN PATIENTS ON TREATMENT WITH NOACs OR VKAs IN REAL-LIFE: CLINICAL PRESENTATION, MANAGEMENT AND OUTCOME

Dr Laura Franco (Abstract S139):

   

RESTORING EFFECTIVE ANTI-TUMOR RESPONSE IN HODGKIN LYMPHOMA WITH NIVOLUMAB

Dr Anas Younes (Abstract S793):

   

EVALUATION OF 243 PATIENTS WITH DELETION 17P CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB: A CROSS-STUDY ANALYSIS OF TREATMENT OUTCOMES

Dr Jeffrey Jones (Abstract S429):

   

A NEW FORM OF INHERITED THROMBOCYTOPENIA (ETV6-RELATED THROMBOCYTOPENIA, ETV6- RT): NEVER JUDGE A BOOK BY ITS COVER!

Dr Federica Melazzini (Abstract S148):